Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience

<b>Background:</b> Immune checkpoint inhibitors (ICIs) have widened the therapeutic scenario of different solid tumors over the last ten years. Gastrointestinal (GI) adverse events (AEs), such as diarrhea and colitis, occur in up to 50% of patients treated with ICIs. <b>Materials and methods:</b> We...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Paola Parente, Brigida Anna Maiorano, Davide Ciardiello, Francesco Cocomazzi, Sonia Carparelli, Maria Guerra, Giuseppe Ingravallo, Gerardo Cazzato, Illuminato Carosi, Evaristo Maiello, Fabrizio Bossa
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	MDPI AG 2022-03-01
Saila:	Diagnostics
Gaiak:	immune checkpoint inhibitor ICI diarrhea colitis PD1 PD-L1
Sarrera elektronikoa:	https://www.mdpi.com/2075-4418/12/3/685
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!